274 related articles for article (PubMed ID: 25080943)
1. A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin.
Kato Y; Kaneko MK
Sci Rep; 2014 Aug; 4():5924. PubMed ID: 25080943
[TBL] [Abstract][Full Text] [Related]
2. LpMab-12 Established by CasMab Technology Specifically Detects Sialylated O-Glycan on Thr52 of Platelet Aggregation-Stimulating Domain of Human Podoplanin.
Kato Y; Ogasawara S; Oki H; Goichberg P; Honma R; Fujii Y; Kaneko MK
PLoS One; 2016; 11(3):e0152912. PubMed ID: 27031228
[TBL] [Abstract][Full Text] [Related]
3. The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity.
Kato Y; Kunita A; Abe S; Ogasawara S; Fujii Y; Oki H; Fukayama M; Nishioka Y; Kaneko MK
Oncotarget; 2015 Nov; 6(34):36003-18. PubMed ID: 26416352
[TBL] [Abstract][Full Text] [Related]
4. ChLpMab-23: Cancer-Specific Human-Mouse Chimeric Anti-Podoplanin Antibody Exhibits Antitumor Activity via Antibody-Dependent Cellular Cytotoxicity.
Kaneko MK; Nakamura T; Kunita A; Fukayama M; Abe S; Nishioka Y; Yamada S; Yanaka M; Saidoh N; Yoshida K; Fujii Y; Ogasawara S; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Jun; 36(3):104-112. PubMed ID: 28504613
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal Antibody LpMab-9 Recognizes O-glycosylated N-Terminus of Human Podoplanin.
Kaneko MK; Oki H; Hozumi Y; Liu X; Ogasawara S; Takagi M; Goto K; Kato Y
Monoclon Antib Immunodiagn Immunother; 2015 Oct; 34(5):310-7. PubMed ID: 26492618
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity.
Kaneko MK; Yamada S; Nakamura T; Abe S; Nishioka Y; Kunita A; Fukayama M; Fujii Y; Ogasawara S; Kato Y
Cancer Med; 2017 Apr; 6(4):768-777. PubMed ID: 28332312
[TBL] [Abstract][Full Text] [Related]
7. Establishment of Mouse Monoclonal Antibody LpMab-13 Against Human Podoplanin.
Ogasawara S; Kaneko MK; Honma R; Oki H; Fujii Y; Takagi M; Suzuki H; Kato Y
Monoclon Antib Immunodiagn Immunother; 2016 Jun; 35(3):155-62. PubMed ID: 27328060
[TBL] [Abstract][Full Text] [Related]
8. Characterization of monoclonal antibody LpMab-3 recognizing sialylated glycopeptide of podoplanin.
Oki H; Ogasawara S; Kaneko MK; Takagi M; Yamauchi M; Kato Y
Monoclon Antib Immunodiagn Immunother; 2015 Feb; 34(1):44-50. PubMed ID: 25723283
[TBL] [Abstract][Full Text] [Related]
9. Antiglycopeptide Mouse Monoclonal Antibody LpMab-21 Exerts Antitumor Activity Against Human Podoplanin Through Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity.
Kato Y; Kunita A; Fukayama M; Abe S; Nishioka Y; Uchida H; Tahara H; Yamada S; Yanaka M; Nakamura T; Saidoh N; Yoshida K; Fujii Y; Honma R; Takagi M; Ogasawara S; Murata T; Kaneko MK
Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):20-24. PubMed ID: 28234556
[TBL] [Abstract][Full Text] [Related]
10. Novel Monoclonal Antibody LpMab-17 Developed by CasMab Technology Distinguishes Human Podoplanin from Monkey Podoplanin.
Kato Y; Ogasawara S; Oki H; Honma R; Takagi M; Fujii Y; Nakamura T; Saidoh N; Kanno H; Umetsu M; Kamata S; Kubo H; Yamada M; Sawa Y; Morita K; Harada H; Suzuki H; Kaneko MK
Monoclon Antib Immunodiagn Immunother; 2016 Apr; 35(2):109-16. PubMed ID: 26937552
[TBL] [Abstract][Full Text] [Related]
11. Chimeric Anti-Human Podoplanin Antibody NZ-12 of Lambda Light Chain Exerts Higher Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity Compared with NZ-8 of Kappa Light Chain.
Kaneko MK; Abe S; Ogasawara S; Fujii Y; Yamada S; Murata T; Uchida H; Tahara H; Nishioka Y; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):25-29. PubMed ID: 28157429
[TBL] [Abstract][Full Text] [Related]
12. Development of Monoclonal Antibody LpMab-10 Recognizing Non-glycosylated PLAG1/2 Domain Including Thr34 of Human Podoplanin.
Ogasawara S; Oki H; Kaneko MK; Hozumi Y; Liu X; Honma R; Fujii Y; Nakamura T; Goto K; Takagi M; Kato Y
Monoclon Antib Immunodiagn Immunother; 2015 Oct; 34(5):318-26. PubMed ID: 26492619
[TBL] [Abstract][Full Text] [Related]
13. Characterization of Monoclonal Antibody LpMab-7 Recognizing Non-PLAG Domain of Podoplanin.
Oki H; Kaneko MK; Ogasawara S; Tsujimoto Y; Liu X; Sugawara M; Takakubo Y; Takagi M; Kato Y
Monoclon Antib Immunodiagn Immunother; 2015 Jun; 34(3):174-80. PubMed ID: 26090595
[TBL] [Abstract][Full Text] [Related]
14. Establishment of Mouse Monoclonal Antibody LpMab-13 Against Human Podoplanin.
Ogasawara S; Kaneko MK; Honma R; Oki H; Fujii Y; Takagi M; Suzuki H; Kato Y
Monoclon Antib Immunodiagn Immunother; 2016 Oct; 35(5):254-258. PubMed ID: 27148766
[TBL] [Abstract][Full Text] [Related]
15. Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2.
Kato Y; Kaneko MK; Kunita A; Ito H; Kameyama A; Ogasawara S; Matsuura N; Hasegawa Y; Suzuki-Inoue K; Inoue O; Ozaki Y; Narimatsu H
Cancer Sci; 2008 Jan; 99(1):54-61. PubMed ID: 17944973
[TBL] [Abstract][Full Text] [Related]
16. Prevention of hematogenous metastasis by neutralizing mice and its chimeric anti-Aggrus/podoplanin antibodies.
Nakazawa Y; Takagi S; Sato S; Oh-hara T; Koike S; Takami M; Arai H; Fujita N
Cancer Sci; 2011 Nov; 102(11):2051-7. PubMed ID: 21824222
[TBL] [Abstract][Full Text] [Related]
17. Development of Core-Fucose-Deficient Humanized and Chimeric Anti-Human Podoplanin Antibodies.
Kaneko MK; Ohishi T; Nakamura T; Inoue H; Takei J; Sano M; Asano T; Sayama Y; Hosono H; Suzuki H; Kawada M; Kato Y
Monoclon Antib Immunodiagn Immunother; 2020 Oct; 39(5):167-174. PubMed ID: 33085938
[TBL] [Abstract][Full Text] [Related]
18. LpMab-23: A Cancer-Specific Monoclonal Antibody Against Human Podoplanin.
Yamada S; Ogasawara S; Kaneko MK; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Apr; 36(2):72-76. PubMed ID: 28387591
[TBL] [Abstract][Full Text] [Related]
19. Characterization of anti-podoplanin monoclonal antibodies: critical epitopes for neutralizing the interaction between podoplanin and CLEC-2.
Ogasawara S; Kaneko MK; Price JE; Kato Y
Hybridoma (Larchmt); 2008 Aug; 27(4):259-67. PubMed ID: 18707544
[TBL] [Abstract][Full Text] [Related]
20. Suppression of Aggrus/podoplanin-induced platelet aggregation and pulmonary metastasis by a single-chain antibody variable region fragment.
Miyata K; Takagi S; Sato S; Morioka H; Shiba K; Minamisawa T; Takami M; Fujita N
Cancer Med; 2014 Dec; 3(6):1595-604. PubMed ID: 25132683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
